CMS Publishes Final Rule for Calendar Year 2026 Physician Fee Schedule for UltraMIST Procedure (CPT code 97610)
CMS adopts Final Rule for 2026 Physician Fee Schedule in line with proposed rule for CPT code 97610
2026 rates for physician offices, home visits, long-term care, and hospitals are in line with the proposed rule and remain materially unchanged from 2025
EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, today provided a business update regarding the anticipated impact of the final rule from the Centers for Medicare & Medicaid Services (“CMS”) for the 2026 Physician Fee Schedule, which were published after the close of business on Friday, October 31, 2025. This schedule established reimbursement rates for CPT codes for the coming calendar year.
Reimbursement for the 97610 code for UltraMIST® products remains materially unchanged for 2026 with payment for treatment provided in the physician office, home visit, long-term care, and hospital settings remaining within $2-4 of 2025 rates. This is in line with the expectations the Company expressed in its preliminary revenue results release on October 6th.
“In light of some changes on other wound care reimbursement, and in response to numerous inquiries from investors and providers about UltraMIST® reimbursement rates for 2026, we wanted to provide this informational update,” said Sanuwave CEO Morgan Frank. “Final 2026 rates for 97610 are in line with the proposed rule and with our prior expectations. Changes for 2026 should be less than 1% with many providers seeing a slight increase in reimbursement. We look forward to discussing this further on our third quarter earnings call.”
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to expected reimbursement levels for the UltraMIST procedure, future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as may be required by applicable law.
Contact:
